EQRx, CStone unfurl full lung cancer data for PD-L1 drug in what the partners are calling a first

Kyle Blankenship

As a self-stylized drug pricing disruptor, EQRx has high hopes for its lead PD-(L)1 to offer proof of concept for the entire business model. After touting a win back in May, the biotech is back with full data in lung cancer that could back up an approval.

Patients dosed with EQRx and CStone Pharmaceuticals’ sugemalimab posted median progression-free survival of 9 months compared with 5.8 months for patients given placebo (p=0.0026), according to full data from the Phase III GEMSTONE-301 study in Stage III non-small cell lung cancer set to be presented at this weekend’s #ESMO21.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

EQRx, CStone unfurl full lung cancer data for PD-L1 drug in what the partners are calling a first

Kyle Blankenship

Unlock this article instantly by becoming a free subscriber.

Head of Regulated Labs Market Strategy

Benchling

San Francisco, CA, USA

Drug and biotech companies join lobbying push on China bill as scrutiny of WuXi continues

Roche unruffled by China bill as it looks to grow roots in the region

FDA's biologics chief Peter Marks previews accelerated approval guidance

Cancer testing company Freenome to lay off 100 employees

Roche doubles down on high-impact projects after slashing 20% of its pipeline

Following lower-than-expected profits, Evotec plans to cut costs, completes CEO search

EQRx, CStone un­furl full lung can­cer da­ta for PD-L1 drug in what the part­ners are call­ing a first

Unlock this article instantly by becoming a free subscriber.

more like this

Benchling

San Francisco, CA, USA

EQRx, CStone unfurl full lung cancer data for PD-L1 drug in what the partners are calling a first